Intermittent dosing of RMC-4630, a potent, selective inhibitor of SHP2, combined with the MEK inhibitor cobimetinib, in a phase 1b/2 clinical trial for advanced solid tumors with activating mutations of RAS signalingJohanna C. Bendell, S.‐H.I. Ou, M. Koczywas et al.|European Journal of Cancer|2020Cited by 27